NCT05501665 - Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 9, 2023

Primary Completion Date

February 1, 2026

Study Completion Date

February 1, 2027

Conditions

Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage III Lung Cancer

Interventions

PROCEDURE

Biospecimen Collection

Correlative studies

DRUG

Carboplatin

Given carboplatin

PROCEDURE

Computed Tomography

Undergo PET/CT

OTHER

Fludeoxyglucose F-18

Given IV

DRUG

Nab-paclitaxel

Given nab-paclitaxel

BIOLOGICAL

Pembrolizumab

Given pembrolizumab

DRUG

Pemetrexed

Given pemetrexed

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

RADIATION

Radiation Therapy

Undergo radiation therapy

OTHER

[18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan

Undergo PET scan

BIOLOGICAL

Ipilimumab

Given Ipilimumab

BIOLOGICAL

Nivolumab

Given Nivolumab

BIOLOGICAL

Cemiplimab

Given Cemiplimab

BIOLOGICAL

Atezolizumab

Given Atezolizumab

Trial Locations (1)

37232

RECRUITING

Vanderbilt University/Ingram Cancer Center, Nashville